Polaryx Therapeutics, Inc. (PLYX)
Nasdaq: PLYX · Pharmaceutical Preparations · Paramus, NJ · filing with the SEC since 2025
Who owns Polaryx Therapeutics, Inc.
As filed with the SECHolders of 5% or more
1
Alex Keun Mo Yang holds 48% of Common stock, par value $0.0001 per share ("Common Stock"), as its SCHEDULE 13D filed Feb 5, 2026 says.
Directors and officers
8
report now, of 8 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 1 named at left.
Holders of 5% or moreshare of the class, as filed
Alex Keun Mo Yang
SCHEDULE 13D · filed Feb 5, 2026 · Common stock, par value $0.0001 per share ("Common Stock")
What PLYX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Mstone Partners Healthcare Limited
An entity · consolidated entity · owns, named in the 10-K filed Mar 24, 2026
Rush University Medical Center
An entity · consolidated entity · owns, named in the 10-K filed Mar 24, 2026
Insider tradesForm 4
0sales
2purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$400,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window2 of 8 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Landis G. Michael | Chief Financial Officer | 0 | $0 | 0 | 1 | $0 |
| Mstone Partners Healthcare Ltd | director | 0 | $0 | 0 | 1 | $400,000 |